Draper feels that Teladoc remains overly exposed to the consumer segment, as it derives roughly 40% of its revenue from such users. A strong dollar also won't help; as a telehealth services provider, of course it's not particularly constrained by borders. As for business spending, the analyst wrote of a "challenging macro environment that is elongating sales cycles in enterprise decisions."
https://www.fool.com/investing/2022/08/17/why-teladoc-health-was-a-sickly-stock-today/